Repare Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Repare Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Repare Therapeutics Inc Strategy Report
- Understand Repare Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Repare Therapeutics Inc (Repare Therapeutics) is a clinical-stage precision oncology company. Its products include lunresertib, a PKMYT1 inhibitor, camonsertib, an ATR inhibitor, RP-1664, a PLK4 inhibitor, and RP-3467, a Polo ATPase inhibitor. Repare Therapeutic utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company operates under the brand SNIPRx. It operates in the US and Canada. Repare Therapeutics is headquartered in St-Laurent, Quebec, Canada.
Headquarters
Canada
Address
Building 2, Suite 270, 7171 Frederick-Banting, St-Laurent, Quebec, H4S2A1
Website
www.reparerx.com
Telephone
1 857 4127018
No of Employees
179
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RPTX (NASD)
Revenue (2022)
$51.1M
-61.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-222.9%
(2022 vs 2021)
Market Cap*
$135.0M
Net Profit Margin (2022)
XYZ
-732.7%
(2022 vs 2021)
* As of and is in US$
Repare Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Lunresertib: Cancer | SNIPRx |
| Camonsertib: Cancer | |
| RP-1664: Cancer | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Repare Therapeutics Inc | Pfizer Inc | GSK plc | Exelixis Inc | Blueprint Medicines Corp |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | United Kingdom | United States of America | United States of America |
| City | St-Laurent | New York | Brentford | Alameda | Cambridge |
| State/Province | Quebec | New York | England | California | Massachusetts |
| No. of Employees | 179 | 88,000 | 70,212 | 1,310 | 655 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas Civik | Chairman | Executive Board | 2021 | 55 |
| Lloyd M. Segal | Chief Executive Officer; President; Director | Executive Board | 2016 | 60 |
| Steve Forte | Chief Financial Officer; Executive Vice President | Senior Management | 2019 | 43 |
| Maria Koehler | Chief Medical Officer; Executive Vice President | Senior Management | 2019 | 67 |
| Michael Zinda, Ph.D. | Executive Vice President; Chief Scientific Officer | Senior Management | 2019 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer